Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA: Rapid Antigen COVID-19 Tests At Risk For False Positives

Executive Summary

An alert from the agency warns that the tests, which have become widely used for their speed and portability, carry a risk of false positives.

You may also be interested in...



FDA Eager To Authorize More Rapid Antigen COVID-19 Tests

The US FDA’s diagnostics chief says the agency isn’t seeing many submissions for rapid antigen tests, but is eager to authorize them. 

First Rapid COVID-19 Antigen Test Gets Green Light

In a potential game-changer in the ongoing fight to expand COVID-19 testing, the FDA has authorized a new kind of test that can be used by certain health care providers on-site to diagnose patients with the SARS-CoV-2 virus within minutes instead of days.

Diagnostics Makers Aim To Produce 25 Million COVID-19 Tests By End Of April

The head of the largest medical device lobby group told reporters the industry hopes to get 25 million diagnostic tests produced by the end of the month to fight the ongoing coronavirus pandemic in the US.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel